Navigation Links
BMP Sunstone Announces Official Launch of Ferriprox in PRC
Date:6/26/2008

Company Holds Launch Events Throughout Cities in Guangdong and Guangxi

Provinces

PLYMOUTH MEETING, Pa., June 26 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP; "BMP Sunstone" or the "Company") today announced the official launch of Ferriprox in the People's Republic of China. The Company will market and distribute Ferriprox under its five-year licensing agreement with Apotex, Inc. As part of the launch, the Company has held physician seminars in cities throughout Guangdong and Guangxi provinces.

Ferriprox(R) treats iron overload in the bloodstream which is often associated with thalassemia, a disease that can lead to organ damage and heart failure. Thalassemia is particularly prevalent in humid environments, like in Southern China, where it is estimated that 7-8% of the population needs treatment for the disease. Ferriprox(R) is currently sold in over 50 countries worldwide and is already approved for sale by China's State Food & Drug Administration ("SFDA"). Ferriprox is the only oral formulation in the class of iron chelator in China, and has proven to be very effective in reducing chronic iron overload, especially in the heart.

"We are pleased to introduce a product that could help a portion of the 15.0 million people in China who develop thalassemia each year. While many physicians are already aware of the relative benefits of Ferriprox, we are excited to further their understanding of Ferriprox at our launch events held this week in Guangdong and Guangxi provinces, including in Guangzhou, which is one of our largest potential markets. This event, targeted to doctors and local distributors, features internationally-renown physician experts in the fields of cardiology and hematology, as well as Dr. Michael Spino, President of ApoPharma Inc.," stated David Gao, Chief Executive Officer of BMP Sunstone.

Gao continued, "Ferriprox is a cost-effective thalassemia treatment, which we believe will result in greater drug compliance than competing injectable formulations. We also feel strongly that our sales and marketing capabilities can create a compelling addressable market and our distribution relationships can bolster our sales performance. We continue to believe that Ferriprox can have a meaningful revenue contribution for BMP Sunstone in 2009 and beyond."

About Apotex Inc.

Apotex Inc. is the largest Canadian-owned pharmaceutical company, headquartered in Ontario with 5,500 employees and 21 facilities. It exports medicines to 115 countries and has an R&D budget expenditure planned of $2.0 billion over the next 10 years. Apotex researches, develops and manufactures over 300 medicines and fills over 72 million prescriptions in Canada per year.

About ApoPharma Inc.

ApoPharma Inc. is a Canadian pharmaceutical company that is devoted to the discovery and development of new medications to treat disorders of iron metabolism and also selected diseases of the skin. ApoPharma is a subsidiary of Apotex Inc., which is one of the most successful generic pharmaceutical companies in the world. Ferriprox has been approved in 54 countries for the treatment of iron overload in thalassemia and was the first oral iron chelator to be approved in Europe.

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the effectiveness of Ferriprox, increased drug compliance of Ferriprox compared to competing injectable formulations, the ability of the Company to develop an addressable market for Ferriprox, the ability of the Company's distribution relationships to bolster the Company's sales performance of Ferriprox and the revenue contribution of Ferriprox to the Company in the future. These statements are subject to uncertainties and risks including, but not limited to, Apotex Inc. ability to supply sufficient quantities of Ferriprox to the Company, the acceptance of Ferriprox in the Chinese market, the efficiency with which Ferriprox is introduced into the Company's distribution network and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward- looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward- looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BMP Sunstone Announces Participation in June Investor Conferences
2. BMP Sunstone Reports First Quarter 2008 Financial Results
3. BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief
4. BMP Sunstone Announces Participation in May Investor Conferences
5. BMP Sunstone to Report First Quarter 2008 Financial Results
6. BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
7. Elsevier announces 2007 journal impact factor highlights
8. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
9. Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards
10. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
11. DST Systems, Inc. Announces Notification of Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... is proud to partner with AquaShieldUSA, the country's oldest waterproof cast protector ... and medical supply stores, the largest selection of daily, night, weatherproof and waterproof ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... successful events, attracting medical professionals from around the globe who attended a week’s ... Opening Ceremonies Sunday, April 17 included the introduction of the 2016 ARRS Distinguished ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the ... of childhood mortality. This is particularly true in underdeveloped parts of Africa where clean ... of New England’s campus in Tangier, Morocco, will examine this global health issue and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Year at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is ... and safety. The Healthy Ageing division can include everything from antioxidants, lipids, proteins, ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing ... Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in July ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
Breaking Medicine Technology: